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Summary An 84-year-old female patient with a past medical history signiﬁcant for hyperten-
sion and diabetes mellitus, was admitted to the Emergency Department with acute coronary
syndrome and complete atrioventricular block. She underwent a successful primary percu-
taneous coronary intervention. Ten minutes following tiroﬁban administration, the patientAcute coronary
syndrome;
Diffuse alveolar
hemorrhage
complained of hemoptysis and severe dyspnea. After chest X-ray and diagnostic bronchoscopy,
she was diagnosed with diffuse alveolar hemorrhage. She died because of respiratory insufﬁ-
ciency on the third day of hospitalization. We present the ﬁrst tiroﬁban-related diffuse alveolar
hemorrhage case caused with half of the recommended dose of tiroﬁban used in the setting of
non-ST-elevation myocardial infarction.
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latelet activation and aggregation play a key role in acute
oronary syndromes (ACS). Glycoprotein IIb/IIIa (GP IIb/IIIa)
eceptor complex, which is found in large amounts on
he activated platelets, forms ﬁbrinogen bridges between
latelets. This process constitutes the ﬁnal common path-
ay in platelet aggregation regardless of stimulus type and
s targeted by many antiplatelet regimens in cardiology.
ow, GP IIb/IIIa antagonists are used frequently and effec-
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ively in ACS to inhibit platelet aggregation and thrombus
ormation. Although they increase minor hemorrhagic com-
lications, we present an uncommon and lethal hemorrhagic
omplication of tiroﬁban in a patient who underwent pri-
ary percutaneous coronary intervention.
ase report
n 84-year-old female patient with a past medical history
igniﬁcant for hypertension and diabetesmellitus was admit-
ed to the emergency service because of squeezing chest
ain lasting 2 h. Electrocardiogram (ECG) showed complete
trioventricular block, escape rhythm with a rate of 38 bpm
Fig. 1A). The patient was diagnosed with ACS and then sent
o the catheterization laboratory following 300mg acetylsal-
Published by Elsevier Ireland Ltd. All rights reserved.
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eFigure 1 Twelve-lead electrocardiography showing complete
left bundle branch block after primary percutanous coronary in
icylic acid and 600mg clopidogrel loading. After transvenous
pacemaker insertion and 10,000 IU intravenous heparin, suc-
cessful primary percutaneous coronary intervention (PCI)
was performed to the total occlusion, proximal to the left
anterior descending coronary artery with a door—balloon
time of 20min. Angiography of the left coronary system also
showed critical proximal obtuse marginal branch 2 lesion.
Left ventricular end—diastolic pressure was 18mm Hg at
that time.Following primary PCI, ECG in the coronary care unit
revealed sinus rhythm with left bundle branch block
(Fig. 1B). Heart rate and blood pressure were 110 bpm
and 85/50mm Hg, respectively. O2 saturation was 95%
o
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Figure 2 Bedside chest X-ray showing diffuse bilateral pulmonary
in the third day. Cardiac silhouette cannot be seen (B).ventricular block and escape rhythm (A) and sinus rhythm with
ntion (B).
ith pulse oxymetry probe and she was not complaining
f breathlessness. Tiroﬁban was administered along with
ther antiischemic drugs to prevent thrombotic compli-
ations. Because of increased risk of hemorrhage due to
ender and age, half of the recommended bolus and infu-
ion doses were administered, but 10min following tiroﬁban
dministration, the patient complained of hemoptysis and
yspnea. Tiroﬁban infusion was immediately stopped. How-
ver, she had respiratory arrest after rapid decrease of pulse
xymetry values. After endotracheal intubation, aspiration
aterial was noted to be bloody and bedside chest X-ray
howed diffuse inﬁltration of the lungs (Fig. 2A). Activated
lotting time (ACT) with Actalyke® ACT system (Helena Lab-
inﬁltrations on the ﬁrst day (A) and conﬂuence of inﬁltrations
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ratories, Beaumont, TX, USA) and platelet number were
28 s and 193,000/l respectively at that time. Creatinine
as 0.87mg/dL (reference 0.5—0.9mg/dL). Transthoracic
chocardiography revealed hypokinesia of interventricular
eptum, anterior and anterolateral walls with a left ventric-
lar ejection fraction of 25%. Hematocrit level progressively
ecreased from 32.5% to 23.8% (reference 35—47%) on the
ame day and two units of erythrocyte suspension were
ransfused. The working diagnosis was acute left heart fail-
re with pulmonary edema on that day.
On the second day, need for high concentrations of
nspired oxygen fraction (FiO2) disappeared and arterial
lood gas measurements showed progressive improvement
nder continuous positive airway pressure mode of mechan-
cal ventilation; 75mg clopidogrel and 2000 IU enoxaparine
id were prescribed, but bronchoscopy reported diffuse
lood contamination of the bronchial tree without any active
leeding point on the same day. At that time, the working
iagnosis was diffuse alveolar hemorrhage. Acetylsalicylic
cid and enoxaparine were stopped.
On the third day, only 75mg clopidogrel was prescribed
s an antithrombotic agent to prevent stent thrombosis
ccording to almost normal arterial blood gas tests and good
edical condition. Then unexpectedly, oxygen saturation
ecame worse even with 100% FiO2 in the following hours.
edside chest X-ray showed increase of inﬁltrations in both
ungs (Fig. 2B). Her respiratory condition did not show any
rogress and she died on the same day.
iscussion
n our patient, tiroﬁban was felt to be the responsible
gent for diffuse alveolar hemorrhage. She had no history
f smoking, hemoptysis, or lung disease. Previous chest
-rays were normal. However, hemoptysis, widespread pul-
onary consolidations, and severe dyspnea developed in
nly 10min following tiroﬁban administration. On the other
and, although seven cases of diffuse alveolar hemorrhage
ollowing tiroﬁban administration have been reported in
he literature, no cases with diffuse alveolar hemorrhage
s a complication of isolated acetylsalicylic acid, clopi-
ogrel, or heparin administration have been presented to
ate. A large-scale retrospective analysis of 5458 acute
yocardial infarction (AMI) patients treated with abciximab
r eptiﬁbatide and 4136 AMI patients treated without GP
Ib/IIIa inhibitors found that GP IIb/IIIa inhibitors statistically
ncrease the risk of diffuse alveolar hemorrhage [1]. A total
f 11 patients showed typical signs (dyspnea, hemoptysis,
rterial hypoxemia, pulmonary radiographic changes, and,
f possible, bronchoscopic signs) of diffuse alveolar hemor-
hage in the GP IIb/IIIa inhibitor group. Only one patient in
he control group presented with a similar clinical picture
ut that patient had received thrombolytic therapy with
eteplase and underwent emergent coronary artery bypass
raft.
GP IIb/IIIa that is expressed on the surface of activated
latelets has a central role in platelet aggregation through
inding ﬁbrinogen and von willebrand factor to platelets
nd crosslinking them. Since the presence of platelet rich
hrombus and beneﬁt of acetylsalicylic acid in ACS are well
nown, GP IIb/IIIa antagonists have been used to inhibit
f
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his ﬁnal common pathway. So, the adjunctive use of GP
Ib/IIIa antagonists is recommended for patients with ST-
levation MI at the time of primary PCI and for high-risk
ngina pectoris/non-ST-elevation MI patients for whom inva-
ive strategy is planned [2,3].
Bleeding is the most frequent side effect due to GP
Ib/IIIa antagonists. The ADMIRAL (Abciximab before Direct
ngioplasty and Stenting in Myocardial Infarction Regard-
ng Acute and Long-term Follow-up) study reported some
omplications in acute ST-elevation MI patients in whom
bciximab had been used during primary PCI. A total of 300
atients with AMI were randomly assigned, in a double-blind
ashion, either to abciximab plus stenting (149 patients)
r placebo plus stenting (151 patients) before they under-
ent coronary angiography. In the abciximab group, there
as 0.7% major bleeding, 12.1% minor bleeding, 6% groin
ematoma with minor bleeding, 4.7% thrombocytopenia,
nd 1.3% severe thrombocytopenia. A presumably more
ethal complication of GP IIb/IIIa antagonists is diffuse alve-
lar hemorrhage, which is, fortunately, encountered rarely
n daily clinical practice.
The ﬁrst diffuse alveolar hemorrhage cases due to abcix-
mab and tiroﬁban were reported in 1997 by Sitges and
illa [4] and in 2000 by Ali et al. [5], respectively. Although
he exact incidence is unknown, in a study examining 1020
atients who received GP IIb/IIIa antagonists and underwent
CI, seven patients were diagnosed with diffuse alveo-
ar hemorrhage and two of them expired. The incidence
f pulmonary hemorrhage for abciximab, eptiﬁbatide, and
iroﬁban was 0.7%, 0.5%, and 0.9%, respectively [6]. Another
tudy examining 2553 patients who underwent coronary
ngiography and received abciximab, reported the inci-
ence of severe pulmonary hemorrhage as 0.27% [7]. In the
ame study, there was no severe pulmonary hemorrhage in
he control group, which consisted of 5412 patients that
nderwent coronary interventions without abciximab. On
he other hand, Iskandar et al. [1] reported diffuse alveolar
emorrhage incidence as 0.33% (6 of 1810) for eptiﬁbatide
nd 0.14% (5 of 3648) for abciximab in the setting of AMI.
Tiroﬁban is one of the most commonly used GP IIb/IIIa
ntagonists. It is a non-peptide competitive antagonist of
he GP IIb/IIIa receptor and most of its inhibitory effects
isappear after 4 h.
Even though the exact pathophysiology is still not fully
nderstood, increased pulmonary capillary wedge pressure
PCWP) is a common risk factor in almost all patients. Left
entricular systolic dysfunction and congestive heart failure
6,8], sudden myocardial stunning due to ACS, as in our case
8—10], chronic obstructive pulmonary disease and related
ulmonary hypertension are leading causes of increased
CWP and main predisposing factors for diffuse alveolar
emorrhage during GP IIb/IIIa inhibitor administration [7,8].
ost of the patients with this catastrophic complication had
prolonged ACT time during GP IIb/IIIa inhibitor adminis-
ration [6—9] that can provoke or maintain the hemorrhage.
n our case, ACT was prolonged and we propose that it con-
ributed to rapid initiation of the hemorrhage within 10min
ollowing tiroﬁban administration.
GP IIb/IIIa antagonist-related diffuse alveolar hemor-
hage has a high mortality rate that was calculated as
3—44% from two patient series [7,8]. Only seven tiroﬁban-
elated severe alveolar hemorrhage patients have been
[
plicating the treatment of acute coronary syndrome. HeartDiffuse alveolar hemorrhage due to tiroﬁban
reported to date and four of them expired. So with our
patient, tiroﬁban-related severe alveolar hemorrhage mor-
tality can be calculated as 62%.
New antithrombotic drugs and new doses of these drugs
are increasingly used in cardiology practise. So predeter-
mined GP IIb/IIIa inhibitor doses in primary PCI may need
some changes. Different loading doses of clopidogrel may
affect the hemorrhagic complications of GP IIb/IIIa antago-
nists. We could not ﬁnd any study comparing diffuse alveolar
hemorrhage rates after 300mg versus 600mg clopidogrel
loading in patients undergoing primary PCI with GP IIb/IIIa
antagonists. In our case half of the recommended bolus and
infusion doses of tiroﬁban caused diffuse alveolar hemor-
rhage.
In conclusion, diffuse alveolar hemorrhage is a rare but
potentially lethal complication of GP IIb/IIIa antagonists.
They should be used very carefully especially in patients
having increased PCWP and when other antithrombotic
drugs are used. It is clear that weight-adjusted heparin to
obtain ACT of 200—250 s will also decrease the risk [11].
Early diagnosis may prevent mortality in some patients. As
the signs and the symptoms of this condition are rather
non-speciﬁc, high clinical suspicion is needed to establish
the correct diagnosis. Opaciﬁcations in chest X-rays and
dyspnea are also common in acute MI patients, but all
invasive cardiologists should also consider diffuse alveo-
lar hemorrhage especially in the presence of hemoptysis
and/or a sudden fall in hemoglobin levels. Thorax computed
tomography and bronchoscopy give valuable information
for differential diagnosis. Treatment is mainly supportive
and involves discontinuation of all possible antithrombotic
agents, respiratory support, blood transfusion, and platelet
infusion especially in abciximab-related hemorrhages. But
more importantly, possible beneﬁts and risks of GP IIb/IIIa
antagonists should be evaluated carefully in patients having
multiple predisposing factors, such as elderly patients using
multiple antithrombotic drugs or patients with high PCWP. In
our case, half of the recommended bolus and infusion doses
of tiroﬁban caused diffuse alveolar hemorrhage. So, even
lower doses of GP IIb/IIIa antagonists may not be safe in this
population.
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